ClinicalTrials.gg
CompletedNCT00195273Updated Apr 28, 2010Results posted

Study Evaluating Sirolimus in Kidney Transplant Recipients

A Phase 3 interventional study of sirolimus and cyclosporine in Graft vs Host Disease and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-28.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing sirolimus in Graft vs Host Disease — 2 open to participants now, 5 under way, none of them phase 3. Sirolimus · Graft vs Host Disease.

Enrollment
11th of 34
61 · median 34
Started
2004
with 1 other
Phase 3
6 of 35
none open now
Registered
11th of 35
by date
Lead sponsor
5 of 35
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 35 studies testing sirolimus in Graft vs Host Disease, this one is the 11th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 3, and was the 11th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

2 of the 35 studies testing sirolimus in Graft vs Host Disease are open now. Recruiting first, the newest first:

All 2 open studies →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing sirolimus in Graft vs Host Disease, or all of them as a file.
02

Study summary

The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted patients treated with cyclosporine, mycophenolate and corticosteroids.

03

Conditions studied

  • Graft vs Host Disease
  • Kidney Transplantation

Browse trials for

Keywords

  • Kidney
  • Transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kidney transplantation
  • Donor must be at least 60 years old.

Exclusion criteria

Exclusion Criteria:

  • Current systemic infection
  • Unstable angina or treatment for serious arrhythmia.
  • Cancer within the previous 5 years.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    1

    Sirolimus + Daclizumab + Mycophenolate + Corticosteroids

    Drug: sirolimus · Drug: mycophenolate mofetil · Drug: corticosteroids · Drug: daclizumab

  • Active comparator
    2

    Cyclosporine + Mycophenolate + Corticosteroids

    Drug: cyclosporine · Drug: mycophenolate mofetil · Drug: corticosteroids

Interventions

  • 15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12

  • Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12

  • 1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events

  • Drugcorticosteroids

    As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day

  • IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation

06

What researchers measure

Primary outcomes

  1. Mean Creatinine Clearance Rate

    Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.

    Time frame: 12 months

Secondary outcomes

  1. Number of Patients With Acute Rejection

    The diagnosis of acute rejection was made via kidney biopsy (Banff criteria). The Banff criteria are standardized diagnostic categories based on histological assessments (e.g., cell types and distributions). Biopsy was performed before initiation of anti-rejection therapy, or at least within 24 hours of the start of therapy.

    Time frame: 3 and 12 months

  2. Patient and Graft Survival

    Graft survival is measured by graft loss which is defined as removal of the transplant.

    Time frame: 12 months

  3. Mean Creatinine Clearance Rate - 3 Months

    Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.

    Time frame: 3 months

07

Results

Posted Sep 7, 2009

Participant flow

Patients were recruited in Sweden from November 2004 to September 2007.

Participant flow — Overall Study
MilestoneSirolimusCyclosporine (CsA)
Started3130
Completed1016
Not completed2114
Withdrew: Adverse event99
Withdrew: Protocol deviation01
Withdrew: Lack of efficacy31
Withdrew: Procedural complications93

Outcome measures

PrimaryMean Creatinine Clearance Rate

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.

Time frame:
12 months
Reported as:
Mean · ml/min
Mean Creatinine Clearance Rate
ml/minSirolimusCyclosporine (CsA)
Mean Creatinine Clearance Rate56.800 ± 21.52253.449 ± 15.497
Statistical analysis
  • Sirolimus vs Cyclosporine (CsA) · ANOVA · p = 0.6081 (Calculated for 12 month analysis)Analysis of variance with treatment group and center as factors
SecondaryNumber of Patients With Acute Rejection

The diagnosis of acute rejection was made via kidney biopsy (Banff criteria). The Banff criteria are standardized diagnostic categories based on histological assessments (e.g., cell types and distributions). Biopsy was performed before initiation of anti-rejection therapy, or at least within 24 hours of the start of therapy.

Time frame:
3 and 12 months
Reported as:
Number · patients
Number of Patients With Acute Rejection
patientsSirolimusCyclosporine (CsA)
3 months39
12 months510
SecondaryPatient and Graft Survival

Graft survival is measured by graft loss which is defined as removal of the transplant.

Time frame:
12 months
Reported as:
Number · patients
Patient and Graft Survival
patientsSirolimusCyclosporine (CsA)
Patient survival3129
Graft loss03
SecondaryMean Creatinine Clearance Rate - 3 Months

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function.

Time frame:
3 months
Reported as:
Mean · ml/min
Mean Creatinine Clearance Rate - 3 Months
ml/minSirolimusCyclosporine (CsA)
Mean Creatinine Clearance Rate - 3 Months55.200 ± 22.40351.878 ± 15.974
Statistical analysis
  • Sirolimus vs Cyclosporine (CsA) · ANOVA · p = 0.4662Calculated for 3 month analysis

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirolimus———
Cyclosporine (CsA)———
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventSirolimusCyclosporine (CsA)
Kidney transplant rejectionImmune system disorders4/318/30
LymphoceleBlood and lymphatic system disorders4/316/30
Cytomegalovirus infectionInfections and infestations3/315/30
PneumoniaInfections and infestations3/314/30
Blood creatinine increasedInvestigations1/313/30
Urinary tract infectionInfections and infestations3/310/30
Wound complicationInjury, poisoning and procedural complications3/310/30
Renal impairmentRenal and urinary disorders3/311/30
AnemiaBlood and lymphatic system disorders2/312/30
Transplant rejectionImmune system disorders0/312/30
Most frequent other events
Showing 10 of 218
Most frequent other events
EventSirolimusCyclosporine (CsA)
AnemiaBlood and lymphatic system disorders15/3117/30
NauseaGastrointestinal disorders7/3110/30
Adema peripheralGeneral disorders10/319/30
ArrhythmiaCardiac disorders9/316/30
Kidney transplant rejectionImmune system disorders3/318/30
OedemaGeneral disorders8/314/30
Urinary tract infectionInfections and infestations8/314/30
LeukopeniaBlood and lymphatic system disorders4/317/30
ConstipationGastrointestinal disorders4/317/30
DiarrheaGastrointestinal disorders7/312/30

Baseline characteristics

Age Continuous
Age Continuous(years)SirolimusCyclosporine (CsA)Total
Mean61.00 ± 10.0059.60 ± 10.1060.31 ± 10.04
Sex: Female, Male
Sex: Female, Male(Participants)SirolimusCyclosporine (CsA)Total
Female91322
Male221739
08

Study locations

3 sites
  • Oslo, N-0027, Norway
  • Gothenburg, SE-413 45, Sweden
  • Uppsala, SE-751 85, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Nov 2004
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Sep 7, 2009
Last update
Apr 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00195273
First posted
Sep 19, 2005
Start date
Nov 2004
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Sep 7, 2009
Last update
Apr 28, 2010

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Norway, Sweden, MedInfoNord@wyeth.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Daclizumab

Start the discussion